Study to be conducted under $3.6 million NIH grant DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), ...

Hospitals with a higher volume of percutaneous microaxial ventricular assist device implantation in the US have fewer deaths among cardiogenic shock patients.

the implantation of LVADs is growing rapidly," he said. The survival of patients on ventricular assist devices has been gradually improving since their inception more than 50 years ago.

The ARIES-HM3 trial analysis found that in advanced heart failure patients with traditional indications for antiplatelet ...

The implantation of a VAD unloads the ventricle in order to diminish myocardial work, allowing a potential myocardial recovery. Patients who fail to demonstrate myocardial recovery within 7 days ...

stroke continues to be a major adverse event after the implantation of the device. Early detection and management of ...

Background Acute kidney injury (AKI) in the context of acute decompensated heart failure (ADHF) encompasses a broad spectrum ...

Heart transplantation (HTx) and the implantation of ventricular assist devices (VAD) are effective surgical treatment options for patients with end-stage heart failure. Nonetheless, for various ...

Patients with cardiogenic shock treated at hospitals with a higher volume of percutaneous microaxial VAD implantation in the US have lower mortality risk. Higher hospital procedure volume of ...

In many circumstances, the initial indication for VAD implantation changes during patient's support. Patients may improve or change their clinical condition (e.g., renal dysfunction, obesity or ...